Sign In
Buy ROIV
$31.25
-0.180 (-0.573%)
At Close: Jun 22, 2026
Roivant Sciences Ltd. (ROIV) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
08:22pm, Tuesday, 09'th Jun 2026
Roivant Sciences Ltd. (ROIV) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Roivant Sciences Ltd. (ROIV) Presents at Jefferies Global Healthcare Conference 2026 Transcript
06:32pm, Wednesday, 03'rd Jun 2026
Roivant Sciences Ltd. (ROIV) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Roivant Sciences Ltd. (ROIV) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
05:24pm, Friday, 29'th May 2026
Roivant Sciences Ltd. (ROIV) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
Roivant: Immunovant's Rheumatoid Arthritis Win Validates The Buy
01:09pm, Thursday, 21'st May 2026
Roivant (ROIV) remains a Buy as its unique 'vant' structure rapidly advances and monetizes blockbuster assets, notably through Immunovant's IMVT-1402 in rheumatoid arthritis. IMVT-1402 delivered stron
Roivant Sciences Ltd. (ROIV) Q4 2025 Earnings Call Transcript
06:20pm, Wednesday, 20'th May 2026
Roivant Sciences Ltd. (ROIV) Q4 2025 Earnings Call Transcript
Roivant Sciences Q4 Earnings Call Highlights
10:08am, Wednesday, 20'th May 2026
Roivant Sciences NASDAQ: ROIV executives used the company's fourth-quarter earnings call to highlight new open-label data for IMVT-1402 in difficult-to-treat rheumatoid arthritis, upcoming pulmonary h
Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates
09:15am, Wednesday, 20'th May 2026
Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.26.
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update
07:00am, Wednesday, 20'th May 2026
BASEL, Switzerland and LONDON and NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the fourth quarter and fiscal year ended March 31, 2026, a
Montes Archimedes Acquisition (ROIV) Upgraded to Buy: Here's Why
01:01pm, Tuesday, 19'th May 2026
Montes Archimedes Acquisition (ROIV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Roivant Sciences Ltd. (ROIV) Presents at Bank of America Global Healthcare Conference 2026 Transcript
04:50pm, Wednesday, 13'th May 2026
Roivant Sciences Ltd. (ROIV) Presents at Bank of America Global Healthcare Conference 2026 Transcript
DURHAM, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the fourth quarter and fiscal year ended March 31, 2026,
BASEL, Switzerland and LONDON and NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, M
Roivant Sciences: Moderna Settlement And Brepocitinib Support A Long-Term Buy
11:05am, Wednesday, 29'th Apr 2026
I believe my original bull case on Roivant Sciences has largely played out, with the stock up sharply since my initial coverage. Brepocitinib is clearly now becoming a broader immunology franchise acr
Roivant Sciences Ltd. (NASDAQ:ROIV) Given Consensus Rating of “Moderate Buy” by Brokerages
04:27am, Wednesday, 15'th Apr 2026
Roivant Sciences Ltd. (NASDAQ: ROIV - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the eleven brokerages that are covering the stock, MarketBeat Ratings reports. One e
Elevate Capital Advisors LLC Sells 36,236 Shares of Roivant Sciences Ltd. $ROIV
04:20am, Sunday, 12'th Apr 2026
Elevate Capital Advisors LLC cut its stake in shares of Roivant Sciences Ltd. (NASDAQ: ROIV) by 31.8% during the undefined quarter, according to its most recent 13F filing with the Securities and Exch
